Clene Nanomedicine, Inc.

Other

Grintellectual Reserve, LLC

Clene Nanomedicine, Inc, a Nevada Corporation

Gr Intellectual Reserve, Llc, a Nevada LLC

Mikhail Merzliakov

Mark Gordon Mortenson

David Andrew Bryce

Adam Robert Dorfman

D Kyle Pierce

Reed N Wilcox

David Kyle Pierce

Anthony Lockett

Arthur Maxwell Grace

Maxwell A Grace

David A Bryce

This invention relates generally to novel methods and novel devices for the continuous manufacture of nanoparticles, microparticles and nanoparticle/liquid solution(s) (e.g., colloids). The nanoparticles (and/or micron-sized particles) comprise a variety of possible compositions, sizes and shapes. The particles (e.g., nanoparticles) are caused to be present (e.g., created and/or the liquid is predisposed to their presence (e.g., conditioned)) in a liquid (e.g., water) by, for example, preferably utilizing at least one adjustable plasma (e.g., created by at least one AC and/or DC power source), which plasma communicates with at least a portion of a surface of the liquid. At least one subsequent and/or substantially simultaneous adjustable electrochemical processing technique is also preferred. Multiple adjustable plasmas and/or adjustable electrochemical processing techniques are preferred. Processing enhancers can be utilized alone or with a plasma. Semicontinuous and batch processes can also be utilized. The continuous processes cause at least one liquid to flow into, through and out of at least one trough member, such liquid being processed, conditioned and/or effected in said trough member(s). Results include constituents formed in the liquid including ions, micron-sized particles and/or nanoparticles (e.g., metallic-based nanoparticles) of novel size, shape, composition, concentration, zeta potential and certain other novel properties present in a liquid.

Continuous, semicontinuous and batch methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) and colloids resulting therefrom

The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are 'clean' relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions. In one embodiment, the condition is mediated by MIF (macrophage migration inhibiting factor).

Gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor

Continuous, semicontinuous and batch methods for treating liquids and manufacturing certain constituents (e.g.,nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) and colloids resulting therefrom

The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are 'clean' relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions In one embodiment, the condition is mediated by MIF (macrophage migration inhibiting factor).

The present invention relates to novel gold-platinum based bi-metallic nanocrystal suspensions that have nanocrystal surfaces that are substantially free from organic or other impurities or films associated with typical chemical reductants/stabilizers and/or raw materials used in nanoparticle formation processes. Specifically, the surfaces are 'clean' relative to the surfaces of metal-based nanoparticles made using chemical reduction (and other) processes that require organic (or other) reductants and/or surfactants to grow (and/or suspend) metal nanoparticles from metal ions in a solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the bi-metallic nanocrystal suspensions. The techniques do not require the use or presence of chlorine ions/atoms and/or chlorides or chlorine-based materials for the manufacturing process/final suspension. The invention further includes pharmaceutical compositions thereof and the use of the bi-metallic nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which metal-based therapy is already known, including, for example, for cancerous diseases or conditions.

Gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the same

A method and apparatus for rapid temperature changes of thin samples is disclosed. The apparatus comprises of a thin-film resistive element embedded in a membrane, a narrow gap between the membrane and a heat sink, and a control circuit. The resistive element acts both as a heater and as a temperature sensor to reduce time constant of the control circuit. The gap between the membrane and the heat sink is filled with gas (e.g., Nor He) acting as cooling medium with low thermal inertia. The temperature controller has a microsecond time constant, which allows adjusting rapidly the power applied to the membrane, depending on heat released/absorbed by a sample during an isotherm or during a given rate of temperature changes. The membrane has low thermal inertia and, coupled with high-speed temperature controller, allows controlled cooling and heating rates up to 100 000 K sand higher. The method can be a core of any setup where controlled fast temperature-time profile of thin or small sample is desirable. The proposed control circuit can be readily applied to the variety of the existing setups with resistive heater.

Method and apparatus for rapid temperature changes

Growing community of inventors

Parkville, MD, United States of America

Mikhail Merzliakov